Business Context and Reporting Period
This Form 8-K, filed on March 15, 2023, reports events occurring on March 9, 13, and 15, 2023, for AgeX Therapeutics, Inc. (AGE). The filing details a strategic financing structure designed to facilitate a potential merger between AgeX and Serina Therapeutics, Inc., alongside a planned spinoff of AgeX's subsidiary, Reverse Bioengineering, Inc. AgeX is an emerging growth company listed on NYSE American.
Key Financial Metrics and Agreements
- Juvenescence Note (Liability): AgeX borrowed $10,000,000 from Juvenescence Limited. The note matures on March 13, 2026, with a 7% origination fee in lieu of interest. It is secured by substantially all of AgeX's assets.
- Serina Note (Asset): AgeX lent the $10,000,000 proceeds to Serina Therapeutics, Inc. The note bears 7% simple interest and matures on March 15, 2026. It is convertible into Serina preferred stock under specific conditions.
- Existing Debt Extension: AgeX extended the repayment date of its outstanding 2020 Loan Agreement with Juvenescence to March 30, 2024.
- Subordination: Existing Serina lenders agreed to subordinate $1,450,000 of their debt to AgeX's Serina Note.
Material Changes and Corporate Actions
- Board Resignation: Dr. Michael D. West resigned from the AgeX Board of Directors on March 9, 2023, to focus on his role as CEO of Reverse Bioengineering, Inc., in anticipation of a potential spinoff. He remains AgeX's CEO.
- Restructuring Strategy: The financing is explicitly intended to fund Serina in contemplation of a merger where AgeX would be the surviving entity. Concurrently, AgeX plans to spin off Reverse Bioengineering to shareholders following a private financing of that subsidiary.
- Security Interest: AgeX granted Juvenescence a security interest in substantially all of its assets, including subsidiary shares, to secure the new $10 million loan.
Outlook, Risks, and Contingencies
Management has not executed a definitive merger agreement with Serina, nor has the AgeX Board approved the Reverse Bio spinoff. There is no assurance that stockholders will approve a merger or that the spinoff will be consummated. Key risks include:
- Transaction Failure: The potential merger and spinoff may not occur due to failure to reach agreement, lack of stockholder approval, or inability to meet listing requirements.
- Default Triggers: The Juvenescence Note contains extensive default provisions, including failure to pay, bankruptcy, or material adverse changes in financial condition. If AgeX fails to consummate a merger by March 13, 2024, it may satisfy the debt by tendering the Serina Note and Serina stock.
- Operational Risks: Future operations depend on the success of Serina's drug delivery platform (POZ) and Reverse Bio's financing, both of which face regulatory and clinical development uncertainties.
Investor Verification Checklist
- Verify the status of the definitive merger agreement between AgeX and Serina, as none has been executed as of the filing date.
- Confirm whether the Reverse Bioengineering spinoff and financing have been approved by the AgeX Board and completed.
- Review the full text of the Security Agreement to understand the extent of assets pledged to Juvenescence.
- Monitor the $10 million loan maturity dates (March 2026) and the specific conditions required to convert the debt into equity.
- Check for the upcoming filing of a Form S-4 Registration Statement regarding the proposed merger.